PDX Portal

Model Details

Patient Information for Model: BCM-PDAC-18

Model Contact

Model: BCM-PDAC-18
Model Contact: Qizhi Cathy Yao
Institution: BCM Pancreas PDX Program
Email: qizhiyao@bcm.edu

Patient Information

Clinical Timeline

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-PDAC-18

Model Details - Initial Implantation of Patient Tissue

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

Histology Information for Model: BCM-PDAC-18

There are no histology images for this model.

Metastasis Information for Model: BCM-PDAC-18

Patient

PDX

Liver

Local

Local recurrence

Lung

Rectum

lymph node

Patient Treatment Information for Model: BCM-PDAC-18

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Gemcitabine/Abraxane	Neoadjuvant	65.06	65.2	51 days	Stable Disease (SD); "NO" progression of disease	No Response (NR)	Completed regimen
25	Gemcitabine	Adjuvant	65.75	66.15	146 days	Stable Disease (SD); Rising CA19-9		Completed regimen
30	Capecitabine	Adjuvant	67.16	67.64	175 days	Stable Disease (SD)		Completed regimen
40	Gemcitabine/Abraxane	Adjuvant	68.26	68.49	84 days	Progressive Disease (PD)		Patient transferred to other hospital